AbbVie Inc. $ABBV Holdings Lowered by Letko Brosseau & Associates Inc.

Letko Brosseau & Associates Inc. trimmed its stake in shares of AbbVie Inc. (NYSE:ABBV) by 2.0% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 285,104 shares of the company’s stock after selling 5,805 shares during the period. Letko Brosseau & Associates Inc.’s holdings in AbbVie were worth $65,143,000 as of its most recent SEC filing.

Other hedge funds have also modified their holdings of the company. Chelsea Counsel Co. purchased a new stake in shares of AbbVie during the third quarter valued at $26,000. Westend Capital Management LLC purchased a new stake in shares of AbbVie during the fourth quarter valued at $29,000. Texas Capital Bancshares Inc TX purchased a new stake in shares of AbbVie during the third quarter valued at $31,000. Legacy Wealth Managment LLC ID lifted its holdings in shares of AbbVie by 115.9% during the fourth quarter. Legacy Wealth Managment LLC ID now owns 136 shares of the company’s stock valued at $31,000 after purchasing an additional 73 shares during the last quarter. Finally, WestEnd Advisors LLC lifted its holdings in shares of AbbVie by 160.4% during the fourth quarter. WestEnd Advisors LLC now owns 138 shares of the company’s stock valued at $32,000 after purchasing an additional 85 shares during the last quarter. 70.23% of the stock is owned by hedge funds and other institutional investors.

Key Headlines Impacting AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: AbbVie presented new data across its blood cancer portfolio at EHA 2026, with multiple oral presentations reinforcing progress in its oncology pipeline and long-term research efforts. AbbVie Presents New Data Across Its Blood Cancer Portfolio at EHA 2026
• Positive Sentiment: AbbVie has also been featured in “final trades” and “buy/hold” style commentary, suggesting traders remain constructive on the stock after its recent run and improved guidance outlook. Final trades: AbbVie, Morgan Stanley, Shake Shack and the CBOE
• Neutral Sentiment: Investors are also watching articles that frame AbbVie as an undervalued dividend-growth name, which supports the bull case but does not bring new company-specific news. Is AbbVie the Most Underrated Dividend Growth Stock in the S&P 500?
• Negative Sentiment: AbbVie terminated its deal with I-Mab to develop a cancer drug, a setback that could be viewed as a pipeline/partnership disappointment even if the financial impact appears limited for now. AbbVie terminates deal with I-Mab to develop cancer drug

AbbVie Price Performance

ABBV opened at $225.25 on Wednesday. AbbVie Inc. has a fifty-two week low of $181.73 and a fifty-two week high of $244.81. The business has a 50-day moving average of $210.40 and a 200-day moving average of $219.12. The company has a market capitalization of $397.97 billion, a PE ratio of 110.96, a price-to-earnings-growth ratio of 0.68 and a beta of 0.32.

AbbVie (NYSE:ABBV) last posted its quarterly earnings results on Wednesday, April 29th. The company reported $2.65 earnings per share for the quarter, topping analysts’ consensus estimates of $2.59 by $0.06. AbbVie had a negative return on equity of 576.45% and a net margin of 5.79%.The company had revenue of $15 billion during the quarter, compared to the consensus estimate of $14.72 billion. During the same period last year, the business earned $2.46 EPS. The business’s quarterly revenue was up 12.4% on a year-over-year basis. On average, equities research analysts expect that AbbVie Inc. will post 14.3 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

ABBV has been the subject of several analyst reports. BMO Capital Markets reaffirmed an “outperform” rating on shares of AbbVie in a report on Monday, March 9th. Piper Sandler increased their price objective on AbbVie from $294.00 to $298.00 and gave the stock an “overweight” rating in a research note on Thursday, May 14th. Morgan Stanley increased their price objective on AbbVie from $270.00 to $278.00 and gave the stock an “overweight” rating in a research note on Thursday, April 30th. Wall Street Zen downgraded AbbVie from a “strong-buy” rating to a “buy” rating in a research note on Sunday. Finally, Weiss Ratings reissued a “hold (c)” rating on shares of AbbVie in a research note on Monday. Three research analysts have rated the stock with a Strong Buy rating, sixteen have given a Buy rating and six have issued a Hold rating to the stock. Based on data from MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $253.43.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.